Objective: To describe an unusual presentation of undifferentiated nasopharyngeal malignancy with immunohistochemical features of both diffuse B-cell lymphoma and undifferentiated carcinoma.
Distinction between these lineages is important for treatment and prognostication. For an undifferentiated tumor, the diagnosis of lymphoma generally predicts a better clinical outcome than a diagnosis of carcinoma.
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On the other hand, the occurrence of collision tumors in the human body is extremely rare. The term refers to coexistent but histologically independent tumors occurring in the same organ. The biological behavior of these tumors is difficult to ascertain and clinical awareness and recognition will oftentimes determine the final outcome in terms of disease-free survival time.
This case report will illustrate the significance of immunohistochemistry in identifying the true identity of undifferentiated tumors and the possibility of collision tumors of carcinoma and lymphoma of the nasopharynx or development of secondary malignancy.
CASE REPORT
A 49-year-old female consulted due to one-year progressive hearing loss, aural fullness and occasional tinnitus in the left ear with weight loss. Otoscopy revealed otitis media with effusion and nasal endoscopy showed a nasopharyngeal mass, both on the left. No cervical lymph node enlargement was appreciated. Nasopharyngeal (NP) biopsy was interpreted as undifferentiated malignancy. (Figure 1 ) Immunohistochemical evaluation was positive for lymphoma and B-cell lineage (Figure 2, 3) and negative for T-cell lineage and carcinoma. (Figure 4 , 5) The results were consistent with Diffuse Large B-Cell Lymphoma (DLBCL) and three cycles of Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin and Prednisone (R-CHOP) were started.
After three months of treatment repeat contrast-enhanced CT scan showed no apparent change in tumor size ( Figure 6 ) and a second NP biopsy was read as undifferentiated carcinoma. Immunostaining was positive for cytokeratin ( Figure 7 ) and negative for LCA. (Figure 8 ) Management was shifted to concurrent chemoradiotherapy (CRT) of high-dose 3-weekly Cisplatin and Simultaneous Integrated Boost Intensity Modulated Radiotherapy (SIB IMRT) of 70Gy in 35 fractions.
Four months after concurrent CRT, contrast MRI showed decrease in nasopharyngeal tumor size and absence of cervical adenopathies. (Figure 9 ) A third NP biopsy revealed necrotic tissues with foci of highgrade squamous cell carcinoma. Unfortunately, the patient was lost to follow-up until two months after, when another contrast MRI showed Undifferentiated malignancies of the nasopharynx may resemble large cell or immunoblastic types of malignant lymphoma and may be distinguished from a carcinoma by a positive immunoreactivity for LCA and negative reaction for cytokeratin. 4, 5 This identification is important in undifferentiated tumors because the diagnosis of lymphoma generally predicts a better clinical outcome than diagnosis of carcinoma.
5 Studies have demonstrated a greater incidence of lymphomas in cases of undifferentiated nasopharyngeal malignancy. Gatter et al. further illustrated that when a pathologist is uncertain about the origin of a neoplasm, the tumor is likely (by a factor of 3 to 1) to be lymphoid in origin. 6 In cases where a diagnosis of carcinoma is increase in the bulk of the nasopharyngeal tumor on the left with inferior extension to the level of the orophaynx and possible contralateral involvement. (Figure 10 ) Based on the consensus at a multidisciplinary meeting, a nasopharyngectomy via left maxillary swing was performed, and the final histopathology report was undifferentiated carcinoma. favored, the frequency of it being a lymphoma is higher. 6, 7 Immunostaining was done in this case to reveal the true identity of the tumor. The specimens from the first NP biopsy were immunopositive for LCA and CD20 while cytokeratin and CD3 were immunonegative. LCA antibody for lymphoma and keratin antibody for carcinoma are useful immunohistochemical tools in the differential diagnosis of undifferentiated neoplasms. 7, 8 Non-Hodgkins lymphoma of B and T cell types are immunoreactive to LCA in 93% to 100%. 7, 8 Prior to the start of chemotherapy, numerous laboratory and metastatic evaluations all indicated that the primary tumor was present only in the nasopharynx. Following R-CHOP every three weeks for three cycles, repeat CT scans of the nasopharynx and neck showed no evidence of tumor regression or change in appearance and configuration.
Could this have been a residual mass or another tumor entity? Positron emission tomography combined with a radiotracer 18F-fluoro-2-deoxyglucose (PET-FDG) would have been very useful in detecting the activity of this residual tumor because malignant cells have increased glycolytic activity. 9 In this case, a tissue sample was still a reasonable choice because it can correctly identify the tumor and is cost-effective. 
